Treatment around surgery cut prostate cancer's return by 62% — and trebled the wait before any further therapy

For men with high-risk prostate cancer facing surgery, what happens around the operation matters. In the PROTEUS substudy, presented at the ESMO congress and published in European Urology, a year of hormone therapy plus the drug apalutamide wrapped around radical prostate surgery cut the risk of recurrence or death by 62% and the risk of spread or death by 51%, compared with surgery and hormone treatment pathways without it. Roughly half as many patients needed further therapy within three years, and the typical time before any next treatment more than trebled. Presenter Alberto Briganti of Milan's Università Vita-Salute San Raffaele said the results support the year-long approach as an option for surgical candidates.

SDG 3 · Good health and well-being — Mechanism: tech innovation